Filing Details

Accession Number:
0001651308-19-000085
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-05 20:15:18
Reporting Period:
2019-09-03
Accepted Time:
2019-09-05 20:15:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1651308 Beigene Ltd. BGNE Pharmaceutical Preparations (2834) 981209416
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1683913 Jane Huang C/O Mourant Governance Services (Cayman)
94 Solaris Avenue
Camana Bay, Grand Cayman E9 KY1-1108
Cmo, Hematology No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
American Depositary Shares Disposition 2019-09-03 2,632 $144.41 230 No 4 S Direct
American Depositary Shares Disposition 2019-09-03 230 $144.94 0 No 4 S Direct
American Depositary Shares Disposition 2019-09-04 82 $129.40 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares 291,667 Direct
Footnotes
  1. Each American Depositary Share ("ADS") represents 13 Ordinary Shares.
  2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligation in connection with the vesting of a restricted share award previously granted to the Reporting Person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.88 to $144.84, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.90 to $144.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ADSs, sold at each separate price.
  5. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  6. These shares were acquired under the BeiGene, Ltd. Second Amended and Restated Employee Share Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).